To understand how deregulated innate immune signaling with a TRAF6‐UBE2N inhibitor contributes to the transformation of an MDS‐like disease into AML, especially in the context of mutations in the RUNX1 gene. The gene discussed is RUNX1; the disease is acute myeloid leukemia.